Taluvian

Withdrawn

This medicine's authorisation has been withdrawn

apomorphine

Overview

The marketing authorisation for Taluvian has been withdrawn at the request of the marketing authorisation holder.

Product information

13/07/2004

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

• summary of product characteristics (annex I);
• manufacturing authorisation holder responsible for batch release (annex IIA);
• conditions of the marketing authorisation (annex IIB);
• labelling (annex IIIA);
• package leaflet (annex IIIB).

Product details

• Name of medicine:
  Taluvian
• Active substance:
  apomorphine hydrochloride
• International non-proprietary name (INN) or common name:
  apomorphine
• Therapeutic area (MeSH):
  Erectile Dysfunction
• Anatomical therapeutic chemical (ATC) code:
  G04BE

Pharmacotherapeutic group

Urologicals

Therapeutic indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Taluvian to be effective, sexual stimulation is required.

Authorisation details

• EMA product number:
  EMEA/H/C/000386
• Marketing authorisation holder:
  Abbott S.r.l.

  Abbott S.p.A.; I-04010 Campoverde di Aprilia; (Latina); Italy

• Marketing authorisation issued:
  28/05/2001